The Globe and Mail

Soligenix (NASDAQ: SNGX) Reports Extended Phase 2a Results for SGX302 Gel in Mild-to-Moderate Psoriasis

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on treatments for rare diseases with unmet medical need, reported extended results from its ongoing Phase 2a trial evaluating ...
Seeking Alpha

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

PRINCETON, N.J., Dec. 17, 2025 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat ...
Morningstar

Spinogenix Reports Evidence of Rapid, Sustained Cognitive Improvement in Alzheimer's Patients from Phase 2a Trial of TAZBENTETOL (formerly SPG302)

LOS ANGELES, Dec. 8, 2025 /PRNewswire/ -- Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients ...
pharmaphorum

ADCs shine at ESMO ’23, as pharma makes case for early immunotherapy interventions

Antibody-drug conjugates (ADCs) took centre stage at the European Society of Medical Oncology (ESMO) Congress in Madrid 20 th-24 th October, which was back at full capacity for the first time since ...
Hosted on MSN

Soligenix announces results from phase 2a trial of SGX302

Soligenix (SNGX) announced extended results of its ongoing Phase 2a trial of SGX302, or synthetic hypericin, for the treatment of mild-to-moderate psoriasis. In this extension, or Cohort 3, of the ...